BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Durvalumab: trial readouts and FDA decisions

6 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 6 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: AstraZeneca, AbbVie, Hoffmann-La Roche, Merck Sharp & Dohme LLC. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P2AstraZeneca AZNNCT07081633 Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular CarcinomaHepatocellular Carcinomaactive not recruiting114
2026-12-31 est.P3AstraZeneca AZNNCT05303532 Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With DurvalumabCancerenrolling by invitation214
2027-01 est.P2/P3AbbVie ABBVNCT06109272 A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as aHepatocellular Carcinomaactive not recruiting89
2027-01-08 est.P3AstraZeneca AZNNCT05221840 A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Non-Small Cell Lung Canceractive not recruiting1051
2027-01-18 est.P2AstraZeneca AZNNCT05374603 Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLCLung Canceractive not recruiting47
2027-01-19 est.P3Hoffmann-La RocheNCT05170204 A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung CNon-Small Cell Lung Canceractive not recruiting68

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-27 est.P2AstraZeneca AZNNCT06008093 A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With ChemotherapCarcinoma, Non-Small-Cell Lungactive not recruiting103
2026-09-30 est.P3AstraZeneca AZNNCT05557838 Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCCHepatocellular Carcinomaactive not recruiting214
2026-08-10P3AstraZeneca AZNNCT05211895 A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLCNon-Small Cell Lung Canceractive not recruiting791
2026-06-30P2AstraZeneca AZNNCT06040099 A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Hepatocellular Carcinoma (HCC)active not recruiting58
2026-06-15P3Merck Sharp & Dohme LLC MRKNCT05298423 Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent ChemoraCarcinoma, Non-Small-Cell Lungcompleted610
2026-06-01P3AstraZeneca AZNNCT03682068 Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Unresectable Locally Advanced Urothelial Cancer; Metastatic Urothelial Canceractive not recruiting1246

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.